Announced details
Treatment of pediatric patients with achondroplasia, and the fields of pediatric endocrinology and metabolism
The venue for presenting an abstract concerning the company's clinical trial.
One of the largest academic meetings in Japan in the fields of pediatric endocrinology and metabolism. It provides a forum for specialists, researchers and healthcare professionals to present and discuss the latest research findings and clinical knowledge.
Kitakyushu International Convention Center
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
59th Annual Meeting of the Japanese Society for Pediatric Endocrinology
| Item | Details |
|---|---|
| Names of Products / Services Covered | umedaptanib pegol (anti-FGF2 aptamer / anti-FGF2 RNA aptamer), WAKABA trial |
| Counterparty | Japanese Society for Pediatric Endocrinology (59th Annual Meeting of the Japanese Society for Pediatric Endocrinology) |
| Counterparty overview | One of the largest academic meetings in Japan in the fields of pediatric endocrinology and metabolism. It provides a forum for specialists, researchers and healthcare professionals to present and discuss the latest research findings and clinical knowledge. |
| Relationship with the Company | The venue for presenting an abstract concerning the company's clinical trial. |
| Launch date | 5 to 7 November 2026 (oral presentation scheduled) |
| Applicable area | Treatment of pediatric patients with achondroplasia, and the fields of pediatric endocrinology and metabolism |
| Location | Kitakyushu International Convention Center |
| Source | 59th Annual Meeting of the Japanese Society for Pediatric Endocrinology |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company explains that this will be an important opportunity to deepen understanding of the clinical significance of the WAKABA trial and umedaptanib pegol, as the trial plan and its significance will be presented by a practicing specialist at an academic meeting attended by experts in pediatric endocrinology.